RxDoctor Payments Data

Lawrence Arkin, MD

Ophthalmology · Rome, GANPI 1538263710

Payments from drug & device makers

$1,387in general payments, 2019–2025

Across 61 payments — averaging $22.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$465
  • Tarsus Pharmaceuticals, Inc.$178
  • Alcon$155
  • Ocular Therapeutix, Inc.$154
  • Bausch & Lomb, A Division Of Bausch Health US, LLC$110
  • Aerie Pharmaceuticals, Inc.$87
  • plus $237 from 7 others

What the payments were for

  • Consulting fees$1007%
  • Food & beverage$1,24890%
  • Gifts$393%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,387 in reported general payments places this provider in the 40th percentile of 481 ophthalmology providers in Georgia.

See all ophthalmology providers in Georgia

Medicare billing

Part B allowed, 2024
$243,231
Medicare patients
909
Services billed
2,051

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost106$47,937
Latanoprost1,001$16,668
Brimonidine Tartrate108$15,640
Alphagan PBrimonidine Tartrate36$13,791
RhopressaNetarsudil Mesylate20$12,366
Prednisolone Acetate349$11,911
CombiganBrimonidine Tartrate/Timolol26$9,690
SimbrinzaBrinzolamide/Brimonidine Tart18$8,002
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat325$6,417
Ciprofloxacin Hcl282$3,172
Travoprost17$3,134
Ketorolac Tromethamine114$2,608
Timolol Maleate135$2,372
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol16$1,995
Brinzolamide12$1,514

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Alphagan P, Combigan$465$71,418168 claims
Aerie Pharmaceuticals, Inc.Rhopressa$87$12,36620 claims
AlconSimbrinza$155$8,00218 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 481 ophthalmology providers in Georgia.

Other ophthalmology in Rome

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →